# Milestone Scientific Inc.: financial statements, quarterly

MLSS · NYSE · CIK 855683 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mlss.md) · [Financials](/companies/mlss/financials.md) · [Filings](/companies/mlss/filings.md) · [Insiders](/companies/mlss/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mlss/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [2,059](/filings/0001437749-24-035311.md) | [2,261 d](/filings/0001437749-25-012050.md) | [2,249](/filings/0001437749-25-017171.md) | [1,854](/filings/0001437749-25-026919.md) | [2,514](/filings/0001493152-25-022276.md) | [2,014 d](/filings/0001493152-26-014117.md) | [2,232](/filings/0001493152-26-022701.md) | [2,323](/filings/0001493152-26-037761.md) | [2,360](/filings/0001493152-25-022276.md) | [2,058 d](/filings/0001493152-26-014117.md) | [2,162](/filings/0001493152-26-022701.md) | [2,841](/filings/0001493152-26-037761.md) |
| Cost of revenue | $k | [556](/filings/0001437749-24-035311.md) | [750 d](/filings/0001437749-25-012050.md) | [573](/filings/0001437749-25-017171.md) | [443](/filings/0001437749-25-026919.md) | [678](/filings/0001493152-25-022276.md) | [502 d](/filings/0001493152-26-014117.md) | [585](/filings/0001493152-26-022701.md) | [706](/filings/0001493152-26-037761.md) | [719](/filings/0001493152-25-022276.md) | [556 d](/filings/0001493152-26-014117.md) | [598](/filings/0001493152-26-022701.md) | [931](/filings/0001493152-26-037761.md) |
| Gross profit | $k | [1,503](/filings/0001437749-24-035311.md) | [1,510 d](/filings/0001437749-25-012050.md) | [1,676](/filings/0001437749-25-017171.md) | [1,411](/filings/0001437749-25-026919.md) | [1,836](/filings/0001493152-25-022276.md) | [1,511 d](/filings/0001493152-26-014117.md) | [1,647](/filings/0001493152-26-022701.md) | [1,618](/filings/0001493152-26-037761.md) | [1,641](/filings/0001493152-25-022276.md) | [1,502 d](/filings/0001493152-26-014117.md) | [1,564](/filings/0001493152-26-022701.md) | [1,910](/filings/0001493152-26-037761.md) |
| Research and development | $k | [170](/filings/0001437749-24-035311.md) | [177 d](/filings/0001437749-25-012050.md) | [94.2](/filings/0001437749-25-017171.md) | [315](/filings/0001437749-25-026919.md) | [232](/filings/0001493152-25-022276.md) | [218 d](/filings/0001493152-26-014117.md) | [369](/filings/0001493152-26-022701.md) | [51.8](/filings/0001493152-26-037761.md) | [16.2](/filings/0001493152-25-022276.md) | [12.3 d](/filings/0001493152-26-014117.md) | not reported | [6.6](/filings/0001493152-26-037761.md) |
| Selling, general and administrative | $k | [2,824](/filings/0001437749-24-035311.md) | [3,301 d](/filings/0001437749-25-012050.md) | [3,035](/filings/0001437749-25-017171.md) | [2,868](/filings/0001437749-25-026919.md) | [3,065](/filings/0001493152-25-022276.md) | [3,327 d](/filings/0001493152-26-014117.md) | [3,257](/filings/0001493152-26-022701.md) | [3,031](/filings/0001493152-26-037761.md) | [2,739](/filings/0001493152-25-022276.md) | [2,550 d](/filings/0001493152-26-014117.md) | [2,373](/filings/0001493152-26-022701.md) | [2,946](/filings/0001493152-26-037761.md) |
| Operating income | $k | [(1,507)](/filings/0001437749-24-035311.md) | [(1,980) d](/filings/0001437749-25-012050.md) | [(1,465)](/filings/0001437749-25-017171.md) | [(1,780)](/filings/0001437749-25-026919.md) | [(1,469)](/filings/0001493152-25-022276.md) | [(2,042) d](/filings/0001493152-26-014117.md) | [(1,998)](/filings/0001493152-26-022701.md) | [(1,485)](/filings/0001493152-26-037761.md) | [(1,134)](/filings/0001493152-25-022276.md) | [(1,080) d](/filings/0001493152-26-014117.md) | [(828)](/filings/0001493152-26-022701.md) | [(1,062)](/filings/0001493152-26-037761.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [0.0](/filings/0001437749-23-031950.md) | [0.0 d](/filings/0001437749-24-010029.md) | [0.0](/filings/0001437749-24-017036.md) | [0.0](/filings/0001437749-25-026919.md) | not reported | not reported | not reported | [0.0](/filings/0001437749-25-026919.md) | not reported | not reported | not reported | not reported |
| Net income | $k | [(1,466)](/filings/0001437749-24-035311.md) | [(1,939) d](/filings/0001437749-25-012050.md) | [(1,441)](/filings/0001493152-25-022276.md) | [224](/filings/0001493152-25-022276.md) | [(1,461)](/filings/0001493152-25-022276.md) | [(2,036) d](/filings/0001493152-26-014117.md) | [(1,995)](/filings/0001493152-26-037761.md) | [(1,483)](/filings/0001493152-26-037761.md) | [(1,154)](/filings/0001493152-25-022276.md) | [(1,091) d](/filings/0001493152-26-014117.md) | [(840)](/filings/0001493152-26-037761.md) | [(1,059)](/filings/0001493152-26-037761.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | [(0.02)](/filings/0001493152-25-022276.md) | not reported | [(0.02)](/filings/0001493152-26-022701.md) | [(0.02)](/filings/0001493152-26-037761.md) | [(0.01)](/filings/0001493152-25-022276.md) | not reported | [(0.01)](/filings/0001493152-26-022701.md) | [(0.01)](/filings/0001493152-26-037761.md) |
| Basic EPS | $ per share | [(0.02)](/filings/0001437749-24-035311.md) | not reported | [(0.02)](/filings/0001437749-25-017171.md) | [0.00](/filings/0001437749-25-026919.md) | [(0.02)](/filings/0001493152-25-022276.md) | not reported | [(0.02)](/filings/0001493152-26-022701.md) | [(0.02)](/filings/0001493152-26-037761.md) | [(0.01)](/filings/0001493152-25-022276.md) | not reported | [(0.01)](/filings/0001493152-26-022701.md) | [(0.01)](/filings/0001493152-26-037761.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | period not labelled (2026-04-20) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.0](/filings/0001437749-25-012050.md) | [4.0](/filings/0001437749-24-017036.md) | [5.8](/filings/0001437749-24-026774.md) | [4.8](/filings/0001437749-24-035311.md) | [3.3](/filings/0001493152-26-014117.md) | [2.2](/filings/0001437749-25-017171.md) | [1.3](/filings/0001437749-25-026919.md) | [1.3](/filings/0001493152-25-022276.md) | [1.1](/filings/0001493152-26-022701.md) | [1.2](/filings/0001493152-26-022701.md) | [1.8](/filings/0001493152-26-037761.md) | [2.1](/filings/0001493152-26-037761.md) |
| Current assets | $m | [10.8](/filings/0001437749-25-012050.md) | [10.8](/filings/0001437749-24-017036.md) | [11.5](/filings/0001437749-24-026774.md) | [10.7](/filings/0001437749-24-035311.md) | [9.3](/filings/0001493152-26-014117.md) | [8.6](/filings/0001437749-25-017171.md) | [7.6](/filings/0001437749-25-026919.md) | [8.1](/filings/0001493152-25-022276.md) | [7.5](/filings/0001493152-26-037761.md) | [7.4](/filings/0001493152-26-022701.md) | not reported | [8.1](/filings/0001493152-26-037761.md) |
| Total assets | $m | [11.4](/filings/0001437749-25-012050.md) | [11.4](/filings/0001437749-24-017036.md) | [12.0](/filings/0001437749-24-026774.md) | [11.2](/filings/0001437749-24-035311.md) | [9.8](/filings/0001493152-26-014117.md) | [9.1](/filings/0001437749-25-017171.md) | [8.1](/filings/0001437749-25-026919.md) | [8.5](/filings/0001493152-25-022276.md) | [7.8](/filings/0001493152-26-037761.md) | [8.0](/filings/0001493152-26-022701.md) | not reported | [8.3](/filings/0001493152-26-037761.md) |
| Current liabilities | $m | [3.1](/filings/0001437749-25-012050.md) | [3.6](/filings/0001437749-24-017036.md) | [3.8](/filings/0001437749-24-026774.md) | [3.8](/filings/0001437749-24-035311.md) | [3.7](/filings/0001493152-26-014117.md) | [4.4](/filings/0001437749-25-017171.md) | [3.8](/filings/0001437749-25-026919.md) | [5.0](/filings/0001493152-25-022276.md) | [4.1](/filings/0001493152-26-037761.md) | [4.9](/filings/0001493152-26-022701.md) | not reported | [4.4](/filings/0001493152-26-037761.md) |
| Total liabilities | $m | [3.4](/filings/0001437749-25-012050.md) | [3.9](/filings/0001437749-24-017036.md) | [4.1](/filings/0001437749-24-026774.md) | [4.0](/filings/0001437749-24-035311.md) | [4.0](/filings/0001493152-26-014117.md) | [4.6](/filings/0001437749-25-017171.md) | [4.7](/filings/0001437749-25-026919.md) | [5.9](/filings/0001493152-25-022276.md) | [5.0](/filings/0001493152-26-037761.md) | [5.7](/filings/0001493152-26-022701.md) | not reported | [4.9](/filings/0001493152-26-037761.md) |
| Shareholders' equity | $m | [8.0](/filings/0001493152-26-014117.md) | [7.5](/filings/0001493152-25-022276.md) | [8.0](/filings/0001493152-25-022276.md) | [7.2](/filings/0001493152-25-022276.md) | [5.8](/filings/0001493152-26-037761.md) | [4.5](/filings/0001493152-26-037761.md) | [3.3](/filings/0001493152-26-037761.md) | [2.5](/filings/0001493152-25-022276.md) | [2.8](/filings/0001493152-26-037761.md) | [2.3](/filings/0001493152-26-037761.md) | not reported | [3.5](/filings/0001493152-26-037761.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,053) d](/filings/0001437749-24-035311.md) | [(1,246) d](/filings/0001437749-25-012050.md) | [(1,218)](/filings/0001437749-25-017171.md) | [784 d](/filings/0001437749-25-026919.md) | [(974) d](/filings/0001493152-25-022276.md) | [(1,511) d](/filings/0001493152-26-014117.md) | [(1,008)](/filings/0001493152-26-022701.md) | [(1,764) d](/filings/0001493152-26-037761.md) | [81.8 d](/filings/0001493152-25-022276.md) | [(226) d](/filings/0001493152-26-014117.md) | [86.8](/filings/0001493152-26-022701.md) | [(585) d](/filings/0001493152-26-037761.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | [3.5 d](/filings/0001493152-26-014117.md) | [1.3](/filings/0001493152-26-022701.md) | [4.5 d](/filings/0001493152-26-037761.md) | [6.2 d](/filings/0001493152-25-022276.md) | [3.1 d](/filings/0001493152-26-014117.md) | [1.6](/filings/0001493152-26-022701.md) | [4.1 d](/filings/0001493152-26-037761.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q2 FY2023 (2023-06-30) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [69.6](/filings/0001437749-22-027252.md) | [69.0](/filings/0001437749-22-012645.md) | [70.4](/filings/0001437749-22-020528.md) | [71.0](/filings/0001437749-22-027252.md) | [72.3](/filings/0001437749-24-026774.md) | [80.0](/filings/0001437749-24-026774.md) | [80.0](/filings/0001493152-25-022276.md) | [81.9](/filings/0001493152-26-022701.md) | [82.0](/filings/0001493152-26-037761.md) | [82.3](/filings/0001493152-25-022276.md) | [85.0](/filings/0001493152-26-022701.md) | [93.1](/filings/0001493152-26-037761.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 88,739,185 at 2026-08-11, from the cover of the [10-Q filed 2026-08-13](/filings/0001493152-26-037761.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.